Evaluation of Inhaled Colistin/Fosfomycin as an Adjunctive Treatment for Ventilator‐Associated Pneumonia: A Preliminary Study Authors: Atousa Hakamifard, Mohammad Reza Mohammadi, Alireza Homayouni, Farzin Khorvash, Saeed Abbasi, Behrooz Ataei, Mahnaz Momenzadeh Published: 2025 ABSTRACT ABSTRACTBackground and AimsVentilator‐associated pneumonia (VAP) caused by gram‐negative bacteria is associated with significant complications, mortality, and resource utilization. Over the past decade, there has been growing interest in using fosfomycin to treat multidrug‐resistant gram‐negative infections, particularly when limited viable options remain. This study aimed to investigate the efficacy of inhaled colistin/fosfomycin as an adjunctive treatment for VAP.MethodsIn this triple‐blind clinical trial, participants with VAP caused by extensively drug‐resistant (XDR) Acinetobacter baumannii were randomly assigned to two groups. Both groups received meropenem (2 g as a 4 h extended infusion every 8 h) and intravenous colistin (9 million IU loading dose, followed by 4.5 million IU every 12 h). The control group was treated with inhaled colistin (1 million IU every 8 h), while the intervention group received a combination of inhaled colistin (1 million IU every 8 h) and fosfomycin (80 mg every 12 h). Clinical pulmonary infection score (CPIS) was measured at baseline and upon completion of the intervention. Acute kidney injury (AKI) rates during treatment, as well as clinical response and microbiological outcomes, were compared between the two groups.ResultsWhile the differences were not statistically significant (p = 0.19), the failure rate was lower in the colistin/fosfomycin group (n = 3; 7.7%) compared to the colistin group (n = 7; 18.9%). The colistin/fosfomycin group exhibited a higher microbiological response rate (n = 19; 48.7%) than the colistin group (n = 13; 35.1%), although the difference did not reach statistical significance (p = 0.23). Both groups showed a significant reduction in CPIS; however, there was no statistically significant difference in procalcitonin levels or CPIS changes between the groups. Treatment duration was significantly shorter in the colistin/fosfomycin group (8.97 ± 2.12 days) compared to the colistin group (14.06 ± 3.32 days) (p < 0.001). The incidence of AKI was similar between the groups, with 15 cases (38.5%) in the colistin/fosfomycin group and 13 cases (35.1%) in the colistin group (p = 0.76).ConclusionThe study demonstrated that the addition of inhaled colistin/fosfomycin to the treatment regimen may result in faster recovery and shorter treatment duration for patients with VAP caused by XDR Acinetobacter baumannii.Keywords: Acinetobacter baumannii, colistin, fosfomycin, ventilator‐associated pneumonia Introduction Ventilator‐associated pneumonia (VAP) caused by gram‐negative bacteria results in significant morbidity and mortality [1]. Acinetobacter baumannii (A. baumannii) accounting for approximately 5%–10% of VAP cases in the United States. In Asia, the prevalence of A. baumannii‐associated VAP is higher than in Europe and the United States [2]. One of the main challenges in treating antibiotic‐resistant gram‐negative bacilli is the emergence of extensively drug‐resistant (XDR) A. baumannii [3]. The rising incidence of resistant pathogens and the limited pulmonary penetration of intravenous antibiotics may contribute to clinical treatment failures. Aerosolized antibiotics have been investigated as a direct treatment for lung infections. However, the clinical efficacy of these treatments has been limited by poorly defined administration methods, unsuitable formulations for airway tolerance, small sample sizes, single‐center studies, and a lack of paired controls [4]. Colistimethate sodium, the inactive precursor of colistin, has been widely used in critical care for managing VAP. However, due to its low pulmonary penetration, the effectiveness of intravenous (IV) colistin in treating pulmonary infections has been questioned. Studies have shown that after IV administration, colistin levels are undetectable in the pulmonary tissues and the bronchoalveolar lavage (BAL) fluid of critically ill adults. Given that colistin achieves high concentrations in the respiratory tract with minimal systemic effects, inhaled colistin presents a promising alternative for treating VAP [5]. Fosfomycin is effective against both gram‐positive and gram‐negative organisms. However, its rapid development of resistance when used as monotherapy necessitates its combination with other antimicrobial agents [6]. In response to the growing need for effective treatments against multidrug‐resistant infections, “old” antibiotics such as fosfomycin and colistin have garnered renewed interest [4]. Inhaled aerosolized fosfomycin has been shown to achieve concentrations exceeding 1200 mg/L in the epithelial lining fluid (ELF). Phase II studies evaluating the combination of inhaled fosfomycin and tobramycin in individuals with cystic fibrosis have yielded positive outcomes. Inhaled colistin has also been increasingly used for managing acute and chronic respiratory tract infections, particularly in cystic fibrosis patients [7]. Recent studies show that combining colistin with other agents enhances its effectiveness against A. baumannii, Pseudomonas aeruginosa, Escherichia coli, and Klebsiella pneumoniae, indicating a synergistic effect [7]. Due to the unavailability of intravenous fosfomycin in our region and the observed synergistic effects of colistin and fosfomycin, combining inhaled colistin and fosfomycin, along with intravenous antibiotics, may offer a beneficial treatment strategy for VAP caused by XDR A. baumannii. This study represents the first clinical trial in Iran aimed to determine whether inhaled colistin or inhaled colistin/fosfomycin offers improved efficacy in patients with VAP caused by XDR A. baumannii. At baseline, both study groups had comparable demographic and clinical characteristics. Materials and Methods The present triple‐blind controlled clinical trial was conducted at a referral hospital, from August 2019 to March 2020. The study received ethical approval from the IUMS ethics committee under Grant No: IR.MUI.MED.REC.1398.404. The research protocol was registered in the Iranian Registry of Clinical Trials (IRCT) under the code IRCT20171230038142N12. Study Population All hospitalized patients diagnosed with VAP due to carbapenem‐resistant A. baumannii in intensive care units (ICUs) were included in the study population. Participants were randomly allocated to study groups (1:1 ratio) using computer‐generated randomization. An independent researcher generated the allocation sequence using randomization software, ensuring concealment until after enrollment. Investigators remained blinded to group assignments during participant recruitment. The inclusion criteria were as follows: Age 20–85 years; mechanical ventilation (intubation) for more than 48 h; diagnosis of VAP; and the presence of XDR A. baumannii in endotracheal culture. The exclusion criteria included pregnancy; lactation; history of allergy to colistin and/or fosfomycin; acute respiratory distress syndrome; active pulmonary tuberculosis; concurrent other infections; renal disorders; and the use of any nephrotoxic medications. VAP diagnosis was based on new or progressing infiltration on lung imaging and at least two of the following clinical signs of infection: fever (temperature > 38°C), leukocytosis (white blood cell count > 12,000/mm³), purulent sputum or increased respiratory secretions requiring suction, and a positive tracheal culture [8]. Written informed consent was obtained from all legal representatives. Sample Size The sample size was calculated based on the primary outcome of clinical response. Assuming a 30% difference in response rates between the colistin/fosfomycin (65%) and colistin (35%) groups [9], with a two‐sided alpha of 0.05, 80% power (beta = 0.20), and a 10% dropout rate, we required 38 participants per group (G*Power 3.1). To account for potential variability and ensure robustness, we enrolled 40 participants per group (total N = 80). Microorganism Endotracheal aspiration (ETA) was used for sample collection. Approximately 2–3 mL of respiratory secretion was obtained in a sterile container after suctioning the patients' lung secretions. The sample was immediately transported to the hospital's microbiology laboratory for culture, pathogen identification, and antibiotic susceptibility testing using the disk diffusion method [10]. If XDR A. baumannii was identified in the culture, the patient was included in the study [11]. Interventions The diagnosis of VAP caused by XDR A. baumannii was confirmed, as previously stated. Random allocation software was then used to randomly assign patients with XDR A. baumannii to one of two groups, each containing 40 participants. At baseline, clinical and demographic data were collected, including age, gender, underlying conditions, reasons for hospitalization and ICU admission, recent antibiotic use, prior ICU admissions, blood tests, clinical pulmonary infection score (CPIS), and serum procalcitonin (PCT) levels. All participants received intravenous colistin (loading dose: 9 million IU, followed by 4.5 million IU every 12 h) and meropenem (2 g as a 4 h extended infusion every 8 h), regardless of group assignment. The control group received inhaled colistin (1 million IU every 8 h), while the intervention group received inhaled colistin/fosfomycin (1 million IU every 8 h/80 mg every 12 h). Fosfomycin Preparation The sodium salt of fosfomycin was used to prepare the inhalation solution. We obtained the drug from Jinan Andechem Company Limited. As an inhalation dosage form, disodium fosfomycin demonstrated enhanced nebulization properties and increased water solubility. In this study, fosfomycin solution was prepared at a concentration of 4% w/v, with 2 mL of solution corresponding to 80 mg of the drug. A specific volume (2 mL) of this solution was loaded into the jet nebulizer chamber for administration. Injectable colistin powder (1 mg) was dissolved in sterile distilled water to prepare it for nebulization. The sterile fosfomycin solution was filtered using 100‐nm filters, and the pH was adjusted with a small amount of HCl. To minimize irritation during inhalation and maintain the appropriate tonicity for bodily fluids, the solution was diluted using nebulizer steam. Both colistin and fosfomycin solutions were nebulized separately to prevent potential chemical interactions. Assessments and Outcome Variables The overall median duration of treatment for VAP is 7 days and there are situations in which a shorter or longer duration of antibiotics may be indicated, depending upon the rate of improvement of clinical, radiologic, and laboratory parameters. Based on this fact, follow‐up assessments were conducted at four time points: Days 1, 3, 7, and at the end of treatment. PCT levels were measured twice: once at baseline and again at the conclusion of the treatment. Blood urea and creatinine levels were measured at four different time points. The CPIS, based on the clinical manifestations of VAP, was calculated for each participant. Comparisons were made between groups regarding changes in CPIS over time, treatment duration, and mortality rates. Statistical Analysis Statistical analysis was performed using SPSS, version 26 (IBM Corporation). Continuous quantitative data were expressed as mean ± SD and median (IQR), while qualitative variables were reported as frequency (%). The Kolmogorov–Smirnov test was used to assess data distribution. The χ 2 test compared the frequency distributions of qualitative characteristics between the two groups. The independent samples t‐test and Mann–Whitney U test were applied to compare quantitative variables with normal and nonnormal distributions, respectively, between the two groups. A significant level of p < 0.05 was considered for all analyses. Results A total of 80 participants were assessed for eligibility, with 76 individuals selected based on the inclusion and exclusion criteria. These participants were randomly assigned to either the intervention or control group (into two groups of 40 participants). Three participants in the control group were excluded: two due to death within 48 h of treatment and one because of a change in medication. One was excluded participants because of death in the intervention group, Finally, the final analysis groups included 39 patients (51.3%) in the colistin/fosfomycin group and 37 patients (48.7%) in the colistin group (Figure 1). CONSORT flow diagram. The baseline clinical and demographic characteristics of the patients are summarized in Table 1. No significant differences were observed between the two groups. Table 1Baseline demographic and clinical characteristics of study participants.VariableGroup p Colistin/fosfomycin (N = 39)Colistin (N = 37)Age (years), median (IQR)59 (IQR: 45–72)58 (IQR: 45.5–72)0.71GenderMale21 (53.8)20 (55.6)0.88Female18 (46.2)16 (44.4)The cause of hospitalization in the intensive care unitLoss of consciousness13 (33.3)17 (45.9)0.65Multiple trauma4 (10.3)6 (16.2)Respiratory distress (excluding pneumonia)10 (25.6)6 (16.2)Cerebral hemorrhage5 (15.3)5 (15.3)CVA2 (5.1)0 (0)Surgery5 (12.8)3 (8.1)Presence of underlying disease34 (87.2)32 (86.5)0.93Recent use of antibiotics36 (92.3)29 (78.4)0.09Previous use of carbapenem25 (64.1)16 (43.2)0.07Previous use of colistin3 (7.7)0 (0)0.24Previous hospitalization history in the ICU5 (12.8)9 (24.3)0.2The interval of hospitalization in the ICU to diagnosis of VAP13.7 ± 10.216.3 ± 3.40.5Duration of mechanical ventilation before VAP16.5 ± 12.117.8 ± 3.60.75 Baseline demographic and clinical characteristics of study participants. In the pre‐treatment period, the mean CPIS values did not differ significantly between the groups, as shown in Table 2. However, at 3 days, 7 days, and at the end of the treatment, the mean CPIS score was significantly lower in the intervention group. Intragroup comparisons showed a significant reduction in CPIS scores in both groups (p < 0.001). The CPIS score decline was more pronounced in the intervention group (p < 0.001) (Figure 2). Table 2Mean and standard deviation of clinical pulmonary infection score (CPIS) during the intervention in both groups.TimeGroupMean difference (95% CI)Effect size p (Comparison between groups)Colistin/fosfomycin (N = 39)Colistin (N = 37)At the beginning of diagnosis7.16 ± 0.757.22 ± 0.75−0.06 (− 0.42 to 0.30)0.80.7472 h5.61 ± 0.796.43 ± 0.8−0.82 (− 1.21 to −0.43)1.04< 0.001After 7 days3.73 ± 0.775.2 ± 1.3−1.47 (− 1.94 to −1.00)1.42< 0.001At the end of treatment2.64 ± 0.543.39 ± 0.84−0.75 (− 1.08 to −0.42)1.09< 0.001 p (Comparison over time)< 0.001< 0.001< 0.001* *Comparison between groups over time. Mean and standard deviation of clinical pulmonary infection score (CPIS) during the intervention in both groups. Comparison between groups over time. Changes in CPIS during the treatment period in colistin/fosfomycin and colistin groups. At the start of treatment, the average CRP concentrations were 78.5 ± 25.9 mg/L in the control group and 69.0 ± 24.3 mg/L in the intervention group, with no significant difference between the groups (p = 0.11). PCT concentrations at baseline and the end of treatment, along with blood urea and creatinine levels at specified intervals, are presented in Table 3, along with their means and standard deviations. No significant differences in PCT levels were observed before or after treatment (p = 0.11). Similarly, there were no significant differences in serum creatinine concentrations between the groups at any time point (p = 0.53). Table 3Mean and standard deviation of serum procalcitonin, urea, and creatinine levels in both groups.VariableTimeGroupMean difference (95% CI)Effect size p Colistin/fosfomycin (N = 39)Colistin (N = 37)ProcalcitoninAt the beginning of treatment3.52 ± 0.614.51 ± 0.74−0.99 [−1.32, −0.66]1.480.31** End of treatment0.90 ± 0.221.62 ± 0.59−0.72 [−0.92, −0.52]1.680.22** p (comparison over time)< 0.001< 0.0010.11* CreatinineAt the time of diagnosis1.29 ± 0.881.32 ± 0.78−0.03 [−0.42, 0.36]0.040.89** 72 h1.43 ± 0.981.75 ± 1.12−0.32 [−0.79, 0.15]0.310.48** After 7 days1.75 ± 1.551.71 ± 1.110.04 [−0.60, 0.68]0.030.91** End of treatment2.94 ± 0.992.03 ± 0.420.91 [0.52, 1.30]0.190.43** p (comparison over time)0.120.250.53* Blood ureaAt the time of diagnosis26.2 ± 19.727.68 ± 16.4−1.48 [−10.3, 7.34]0.080.73** 72 h26.2 ± 19.727.68 ± 16.4−1.48 [−10.3, 7.34]0.080.36** After 7 days27.87 ± 19.5630.89 ± 16.01−3.02 [−11.7, 5.66]0.170.25** End of treatment29.32 ± 19.5824.53 ± 13.834.79 [−3.50, 13.08]0.280.25** p (comparison over time)0.390.0610.84* *Comparison between groups over time.**Comparison between groups. Mean and standard deviation of serum procalcitonin, urea, and creatinine levels in both groups. Comparison between groups over time. Comparison between groups. Seven days after treatment, ETA culture results were negative for 13 participants in the control group and 19 participants in the intervention group (48.7% vs. 35.1%), although the difference was not statistically significant (p = 0.23). The intervention group had an average treatment duration of 8.97 ± 2.12 days, compared to 14.06 ± 3.32 days in the control group. The treatment duration was significantly shorter in the intervention group (p < 0.001). One (2.6%) patient in the intervention group and 2 (5%) patients in the control group died. The difference in treatment failure rates between the groups was not statistically significant (p = 0.19), with 3 failures (7.7%) in the intervention group and 7 failures (18.9%) in the control group. Medication‐related complications, including nephrotoxicity, occurred in 28 (36.8%) of the 76 participants, with 15 in the intervention group and 13 in the control group (38.5% vs. 35.1%). However, no significant difference in nephrotoxicity rates was observed between the two groups (p = 0.76). Discussion In this randomized controlled trial, adding inhaled colistin/fosfomycin combination therapy to standard treatment for ventilator‐associated pneumonia (VAP) caused by XDR A. baumannii yielded notable clinical improvements. Although the differences in clinical success rate and microbiological clearance between groups were not statistically significant, the overall trend favored the combination therapy. More importantly, the duration of antibiotic treatment was significantly shorter in the intervention group. Both groups showed a marked reduction in CPIS and serum PCT levels, although the magnitude of reduction was not significantly different between groups. Moreover, the addition of inhaled fosfomycin did not increase the incidence of AKI rates. These findings suggest that inhaled combination therapy may promote faster clinical recovery and reduce the need for prolonged antibiotic courses without adding adverse effects. The global prevalence of treatment failure and mortality caused by multidrug‐resistant (MDR) infections has significantly increased [12]. With the rise of MDR gram‐negative bacteria, colistin treatment has been revisited in recent years. However, prior studies have shown that colistin does not adequately penetrate the pleural cavity or lung parenchyma [13]. Colistin and fosfomycin, two older antibiotics, have regained attention for the treatment of MDR gram‐negative infections, particularly with the advantage of being available in inhaled formulations [7]. Previous studies have indicated a synergistic effect when combining fosfomycin with colistin [14]. The present study found that the addition of inhaled colistin/fosfomycin to intravenous colistin/meropenem led to improved clinical outcomes in patients with VAP caused by XDR A. baumannii. Moreover, the recovery time was significantly shorter in the inhaled colistin/fosfomycin group compared to the inhaled colistin monotherapy group. Additionally, no increase in nephrotoxicity was observed with the addition of inhaled colistin/fosfomycin to intravenous colistin/meropenem. These findings suggest that the combination of fosfomycin and colistin does not result in significant adverse effects [15]. While the rate of complete clinical response was higher in the colistin/fosfomycin group, the difference between the two groups in terms of treatment failure was not statistically significant. These results align with findings from other studies, which demonstrate that fosfomycin is a broad‐spectrum antibiotic effective against a wide range of gram‐positive and gram‐negative infections. Fosfomycin may thus be considered a valuable adjunct for managing XDR A. baumannii infections [16]. Microbiological responses to treatment were observed in 48.7% of participants in the intervention group, compared to 35.1% in the control group. Although the difference was not statistically significant, the higher microbiological response rate in the intervention group suggests that this combination may be more effective in eliminating the pathogen XDR A. baumannii. This enhanced efficacy may be attributed to the synergistic interaction between colistin and fosfomycin. Boncompagni et al. demonstrated that the combination of fosfomycin and colistin, when administered via nebulization at therapeutic levels, exhibited significant synergy against multidrug‐resistant gram‐negative pathogens, particularly those cultured in biofilms. Furthermore, this combination reduced the emergence of subpopulations resistant to both fosfomycin and colistin [7]. Polat et al. found that inhaled colistin could complement intravenous colistin, potentially accelerating bacterial eradication. Mild bronchoconstriction may occur with the initial doses of inhaled colistin, but it typically does not necessitate discontinuation of treatment [17]. In contrast, colistin methanosulfate monotherapy has limitations due to its uncertain conversion to the active form and its high mucin binding, which may reduce its efficacy [4]. A study by Greek researchers demonstrated that fosfomycin effectively eliminated 91.8% of severely drug‐resistant Enterobacteriaceae in vitro [18]. Sirijatuphat et al. conducted a study involving 94 participants with VAP caused by carbapenem‐resistant A. baumannii and found that the group receiving inhaled colistin/fosfomycin showed superior treatment outcomes compared to the group receiving inhaled colistin alone. The colistin/fosfomycin group also demonstrated a reduction in mortality [9]. These results support the notion that combining colistin with fosfomycin can shorten recovery time, reduce treatment duration, and decrease healthcare costs by minimizing inpatient stays. The impact of inhaled tobramycin–fosfomycin in treating VAP caused by A. baumannii was assessed in two clinical trials by Hallal et al. [19] and Le Conte et al. [20], both demonstrating the substance's significant effect in reducing mortality and hospitalization rates in ICU settings. A regimen incorporating fosfomycin has recently shown improved outcomes in all‐cause mortality, along with notable efficacy in microbiological eradication and clinical resolution [21]. Given that colistin and fosfomycin have been shown to act synergistically in vitro, fosfomycin may serve as a valuable adjunctive therapy for pneumonia caused by MDR/XDR A. baumannii strains. Recent studies have demonstrated that fosfomycin achieves therapeutic levels in infected pulmonary tissue, making it a promising alternative for treating infections caused by MDR A. baumannii [22, 23]. In a time‐kill study, the combination of fosfomycin and colistin demonstrated significant antibacterial and synergistic effects within 8 h, reducing the bacterial burden in the lungs at 48 h compared to monotherapies or colistin combined with minocycline [24]. Comparing patients treated with colistin alone to those receiving the fosfomycin‐colistin combination revealed superior microbiological outcomes, improved clinical responses, and reduced mortality in the combination group [9]. Therefore, the positive results observed in this study may be attributed to the synergistic effect of the colistin/fosfomycin regimen against XDR A. baumannii. By contrast, some studies have reported no significant differences with the addition of inhaled or combination therapies. For example, in a recent study from Thailand (Katip et al. [25]), patients with pneumonia caused by carbapenem‐resistant A. baumannii were assigned to receive high‐dose intravenous colistin with or without nebulized colistin. This retrospective analysis of 261 patients found no difference in 30‐day survival between groups (p = 0.418), and no significant difference in clinical response or microbiological eradication. Nephrotoxicity rates were also similar. The authors concluded that in this population, adding nebulized colistin to IV therapy provided no clear benefit in primary outcomes [25]. Moreover, another retrospective study by the same group (Katip et al.) examined 220 patients with carbapenem‐resistant enterobacteriaceae (CRE) infections, comparing IV colistin monotherapy with IV colistin + fosfomycin combination therapy. This study also found no significant difference in 30‐day mortality, clinical response, or microbiological clearance between the groups, suggesting that colistin alone may be as effective as the combination, though the authors noted that further RCTs are needed to confirm this. At first glance, these results may appear to conflict with our findings, which suggested a trend toward improved outcomes with added fosfomycin. However, it is important to recognize key differences in study design and context: Katip's study focused on CRE infections, which included a range of infection types, not exclusively VAP. Fosfomycin was administered systemically, not via inhalation. Their studies were retrospective, whereas ours is a prospective RCT, making direct comparisons inappropriate. This study possesses several key strengths that enhance the credibility of its findings. First, its prospective, randomized controlled design reduces bias and strengthens causal inference. Second, the rigorous selection of patients with VAP due to XDR A. baumannii ensures the relevance of results in challenging real‐world clinical scenarios. Third, the comprehensive assessment of both clinical (CPIS) and laboratory (PCT) outcomes, alongside microbiological response analysis, provides a well‐rounded view of therapeutic effectiveness. Fourth, the homogeneity of study groups and uniform baseline treatment protocols allowed for a clearer evaluation of the intervention's true impact. Finally, this trial represents one of the first RCTs globally—and the first in our country to investigate inhaled fosfomycin in VAP, thereby filling a critical knowledge gap and laying groundwork for future treatment guidelines. Despite these strengths, interpretation of the findings should take several limitations into account. The primary limitations of this study include the small sample size and the fact that it was conducted at a single center. Additionally, because the minimum inhibitory concentration (MIC) test was not available at our center, the study did not determine the MIC for the antibiotics tested and this important limitation affects the interpretation of our study results. Also at the time of this study, newer, broader‐spectrum intravenous drugs effective on gram negative bacilli were not available for the treatment of A. baumannii, and therefore IV colistin was used in this study. Conclusion VAP remains a leading cause of morbidity and mortality in ICU patients, with high treatment failure rates due to MDR/XDR pathogens. This study highlights the potential of adjunctive inhaled therapies. Present findings suggest that inhaled colistin/fosfomycin therapy for VAP caused by XDR A. baumannii results in faster and more favorable clinical outcomes without exacerbating complications such as nephrotoxicity. However, due to the limitations mentioned, further clinical trials are necessary to establish definitive conclusions. Author Contributions Atousa Hakamifard: methodology. Mohammad Reza Mohammadi: investigation. Alireza Homayouni: investigation, validation. Farzin Khorvash: supervision. Saeed Abbasi: investigation, supervision. Behrooz Ataei: supervision. Mahnaz Momenzadeh: writing – original draft, writing – review and editing. Consent Written informed consent was obtained from all the participants. Conflicts of Interest The authors declare no conflicts of interest. Transparency Statement The corresponding author, Mahnaz Momenzadeh, affirms that this manuscript is an honest, accurate, and transparent account of the study being reported; that no important aspects of the study have been omitted; and that any discrepancies from the study as planned (and, if relevant, registered) have been explained. Acknowledgments This study was part of a Specialist's Thesis and was financially supported by the Vice‐Chancellery of Research, Isfahan University of Medical Sciences, under Grant No. 398135. Hakamifard A., Mohammadi M. R., Homayouni A., et al., “Evaluation of Inhaled Colistin/Fosfomycin as an Adjunctive Treatment for Ventilator‐Associated Pneumonia: A Preliminary Study,” Health Science Reports 8 (2025): 1‐9. 10.1002/hsr2.71670. Data Availability Statement The data that support the findings of this study are available from the corresponding author upon reasonable request. References Associated Data Data Availability Statement The data that support the findings of this study are available from the corresponding author upon reasonable request.